Eric S Lightcap

6PUBLICATIONS
49CO-AUTHORS
Molecular targetsBiologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 20, 2025
In Vivo Tumor Growth Control by General Control Nonderepressible 2-Targeting Agents Results from Kinase Activation.

Feven Tameire, Paulina Wojnarowicz, Crissy Dudgeon

|Mar 26, 2024
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator.

Christopher G Thomson, Thomas D Aicher, Weiwei Cheng

|Nov 19, 2023
CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade.

Tomoko Yamamori Morita, Jie Yu, Yukie Kashima

|Sep 21, 2023
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors.

Michael E Stokes, Veronica Calvo, Sho Fujisawa

|Sep 15, 2021
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.

Eric S Lightcap, Pengfei Yu, Stephen Grossman

Pageof 1

Frequent Collaborators

3 joint publications

Alan C Rigby

3 joint publications

Simon J Taylor

3 joint publications

Christopher G Thomson

3 joint publications

David Surguladze